已发表论文

高 CD3D/CD4 比率预示肌肉浸润性膀胱癌的较高存活率

 

Authors Shi MJ, Meng XY, Wu QJ, Zhou XH

Received 16 October 2018

Accepted for publication 7 February 2019

Published 12 April 2019 Volume 2019:11 Pages 2987—2995

DOI https://doi.org/10.2147/CMAR.S191105

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 3

Editor who approved publication: Professor Nakshatri

Background: Bladder cancer is a common malignancy that affects the human urinary tract. Muscle-invasive bladder cancer (MIBC) is aggressive and has poor prognosis. Previous studies have reported that the tumor-infiltrating lymphocytes (TILs) were associated with MIBC outcome; however, inconsistency remains and mRNA level TIL markers’ prognostic significance in MIBC is unclear. 
Materials and methods: In the present study, we reanalyzed data from four public datasets (the Cancer Genome Atlas for investigation; and CIT, GSE5287, and GSE31684 for validation) to examine the prognostic significance of CD3D, CD4, CD8A, CD3D/CD4 and CD3D/CD8A in MIBC. 
Results: We found that the CD3D/CD4 ratio was a stable independent prognostic factor in MIBC (beta = −0.87, = 0.025); high CD3D/CD4 ratio predicted better survival in MIBC, and the power of this association was much stronger in basal-squamous tumors (beta = −4.73, = 2.67E-06). We also noted that the CD4 expression was significantly higher than CD3D (< 0.05), indicating the presence of CD3CD4+ cells which could be immune-suppressing.
Conclusion: The CD3D/CD4 ratio can be viewed as a prognostic marker and a rough measurement for the interaction between immune-effecting CD3+ TILs and immune-suppressing CD3CD4+ cells in MIBC, and this interaction may play a particularly important role in anti-cancer immunity in basal-squamous tumors as it has a very strong association with survival in this subtype, and may be used to select potential responders to immunotherapy.
Keywords: bladder cancer, muscle-invasive, tumor-infiltrating lymphocytes, CD3, CD4, CD8, prognosis, immunotherapy, basal-squamous subtype




Figure 1 Distribution of TIL markers and their ratios. (A) Distribution of CD3D, CD4 and...